Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $45.4 million.

  • Immunome's Cash from Financing Activities rose 1478163.93% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.6 million, marking a year-over-year decrease of 1750.22%. This contributed to the annual value of $240.5 million for FY2024, which is 10662.58% up from last year.
  • As of Q3 2025, Immunome's Cash from Financing Activities stood at $45.4 million, which was up 1478163.93% from -$55000.0 recorded in Q2 2025.
  • Over the past 5 years, Immunome's Cash from Financing Activities peaked at $219.4 million during Q1 2024, and registered a low of -$55000.0 during Q2 2025.
  • Over the past 3 years, Immunome's median Cash from Financing Activities value was $32.7 million (recorded in 2024), while the average stood at $56.4 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 64532647.06% in 2024, then tumbled by 10792.51% in 2025.
  • Immunome's Cash from Financing Activities (Quarter) stood at $55.5 million in 2023, then plummeted by 63.81% to $20.1 million in 2024, then skyrocketed by 125.98% to $45.4 million in 2025.
  • Its Cash from Financing Activities stands at $45.4 million for Q3 2025, versus -$55000.0 for Q2 2025 and $162.2 million for Q1 2025.